Form 4: Bolt Biotherapeutics CEO Randall Schatzman Acquires 654,000 Stock Options

CEO Randall Schatzman of Bolt Biotherapeutics acquired 654,000 stock options on March 4, 2024, while disposing of 235,000 shares.

Summary

• Randall C Schatzman, CEO of Bolt Biotherapeutics, filed a Form 4 with the SEC.
• The filing reports a transaction on March 4, 2024, where Schatzman acquired 654,000 stock options with an exercise price of $1.27.
• These options vest monthly starting January 1, 2024, over a 36-month period, contingent upon continuous service to the Issuer.
• Schatzman also disposed of 235,000 shares.

Sentiment

Score: 5

Explanation: Neutral sentiment. The document primarily reports transactions without expressing a clear positive or negative outlook. The acquisition of options could be seen as positive, but the disposal of shares tempers this.

Positives

• The acquisition of stock options by the CEO could be interpreted as a sign of confidence in the company's future performance.

Negatives

• The disposal of 235,000 shares by the CEO could be interpreted as a lack of confidence in the company's future performance.

Risks

• The vesting of the options is contingent upon the CEO's continuous service, creating a potential risk if the CEO were to leave the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The acquisition of options and disposal of shares are common compensation and portfolio management activities.

Stakeholder Impact

• The transactions may influence investor sentiment regarding Bolt Biotherapeutics.

Key Dates